Aldeyra Therapeutics Inc. (ALDX)
NASDAQ: ALDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ALDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $57.83M
- EPS (TTM)
- -$0.40
- Dividend yield
- None
- 52-week range
- 0.862 – 5.93
- Day range
- 0.8812 – 0.9666
- Volume / Avg
- 1.28M / 1.19M
- Beta
- —
- Shares outstanding
- 60.33M
- Next earnings
- Nov 4, 2026
52-week range
ALDX stock today
Aldeyra Therapeutics (ALDX) closed at $0.9586 on Oct 7, up 4.66% (+$0.0427), versus the S&P 500's 0.22% decline. Shares are 83.8% below their 52-week high of $5.93, set on Jan 30, 2026 and 11.2% above the 52-week low of $0.862, near the bottom of the past year's range. ALDX is down 81.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 82.9%.
Aldeyra Therapeutics has posted a net loss over the last twelve months (EPS of -$0.40), so its P/E ratio is not meaningful. Aldeyra Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Aldeyra Therapeutics
Company profile- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- IPO year
- 2014
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.11
ALDX news
All ALDX news- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowNasdaqAGIO, NVO, ALDX, ACIU
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkNasdaqNVO, ALDX, ACIU, PGEN
- Vertex Posts Positive Phase II Data on Kidney Disease DrugNasdaqVRTX, ALDX, ACIU, PGEN
- Gilead Expands Lenacapavir Access With New PAHO Deal in Latin AmericaNasdaqGILD, ALDX, ACIU, PGEN
- GSK Inks $750M Deal to Add Experimental Blood Cancer TherapyNasdaqGSK, ALDX, ACIU, PGEN
Aldeyra Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACETAdicet Bio Inc. | 6.18 | -1.12% | $57.85M | vs ALDX |
| XLOXilio Therapeutics Inc. | 9.01 | +0.11% | $59.29M | vs ALDX |
| MREOMereo BioPharma Group plc ADR | 0.3528 | +0.77% | $56.34M | vs ALDX |
| CNTBConnect Biopharma Holdings Limited | 0.9447 | +4.34% | $59.49M | vs ALDX |
| CLNNClene Inc. | 3.92 | +1.29% | $55.72M | vs ALDX |
| BOLDBoundless Bio Inc. | 2.64 | +2.72% | $60.05M | vs ALDX |
| ATHEAlterity Therapeutics Limited ADR | 3.32 | -1.48% | $60.45M | vs ALDX |
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.16 | +4.50% | $54.97M | vs ALDX |
Indexes, lists and sector
Aldeyra Therapeutics stock FAQ
What is Aldeyra Therapeutics's stock price today?
ALDX last traded at $0.9586 as of Oct 7, 4:00 PM EDT, up 4.66% on the day. Prices are delayed at least 15 minutes.
When is Aldeyra Therapeutics's next earnings date?
Aldeyra Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.11.
What is the ALDX 52-week high?
The 52-week high for ALDX is $5.93 and the 52-week low is $0.862. The stock is currently 83.8% below its high.